Repatha and Trazodone Interaction: What Patients and Clinicians Need to Know

How Evolocumab Works and Why CYP Interactions Do Not Apply

Evolocumab is a fully human IgG2 monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). It binds circulating PCSK9, preventing that enzyme from degrading LDL receptors on hepatocytes, which allows more LDL cholesterol to be cleared from the bloodstream. The FDA prescribing information for evolocumab states that because the drug is a large-protein biologic, it is not metabolized by cytochrome P450 enzymes, is not a substrate or inhibitor of P-glycoprotein, and is not subject to renal or hepatic elimination pathways in the conventional sense.

This biology matters enormously for interaction screening. The vast majority of small-molecule drug interactions occur at shared CYP enzymes (CYP3A4, CYP2D6, CYP2C9) or at transporter proteins (P-gp, OATP1B1). Evolocumab sidesteps all of these.

Proteolytic Degradation: The Core Reason No Kinetic Interaction Exists

After subcutaneous injection, evolocumab is absorbed over several days (median Tmax approximately 3 to 4 days) and then broken down into amino acids by the same proteolytic pathways that degrade endogenous IgG antibodies. No hepatic microsomal enzyme handles this process. A pharmacokinetic review published in Clinical Pharmacokinetics confirmed that evolocumab does not inhibit or induce CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at any clinically relevant concentration.

What the FDA Label Actually Says About Drug Interactions

The evolocumab (Repatha) prescribing information contains no drug interaction section that lists individual small molecules. That absence is intentional. No dose adjustment is required for co-administered statins, ezetimibe, fibrates, or other cardiovascular drugs. The same logic applies to psychotropic medications, including trazodone.

Trazodone Pharmacology and Its Metabolic Vulnerabilities

Trazodone is a serotonin antagonist and reuptake inhibitor (SARI) approved for major depressive disorder and widely prescribed off-label for insomnia, often at doses of 25 to 100 mg at bedtime. Understanding where trazodone is metabolized explains why certain co-medications do matter, and why evolocumab does not.

CYP3A4 as the Primary Trazodone Pathway

Trazodone is metabolized predominantly by CYP3A4 to its active metabolite meta-chlorophenylpiperazine (mCPP). The FDA prescribing information for trazodone hydrochloride notes that potent CYP3A4 inhibitors (such as ritonavir, ketoconazole, and itraconazole) can increase trazodone plasma concentrations substantially, raising the risk of sedation, hypotension, and cardiac QTc prolongation. Conversely, potent CYP3A4 inducers such as carbamazepine can reduce trazodone exposure, blunting its antidepressant effect.

Evolocumab touches none of these pathways. It neither inhibits nor induces CYP3A4. Trazodone concentrations remain unaffected.

CYP2D6 Minor Pathway

A minor fraction of trazodone is processed via CYP2D6. Drugs that strongly inhibit CYP2D6, including paroxetine and fluoxetine, may modestly increase trazodone exposure. Again, this is irrelevant to evolocumab.

P-Glycoprotein Considerations

Some clinicians ask whether trazodone, as a CNS-active compound, might interact with P-gp substrates. Trazodone is not a clinically significant P-gp substrate or inhibitor at therapeutic doses. Even if it were, evolocumab has no P-gp activity to complicate matters.

Pharmacodynamic Overlap: The One Area Worth Discussing

No pharmacokinetic interaction exists between evolocumab and trazodone. However, pharmacodynamic overlap, meaning additive effects on the same physiological system, deserves a brief discussion. A 2018 analysis in Drug Safety outlined how even non-interacting medications can produce additive CNS depression when one agent has sedating properties.

Trazodone carries significant sedating activity through H1 histamine receptor antagonism and alpha-1 adrenergic blockade. At therapeutic doses for depression (150 to 400 mg/day), sedation is a common adverse effect. At the low doses used for sleep (25 to 100 mg), sedation is essentially the therapeutic goal.

Evolocumab itself does not cause CNS sedation. Its most common adverse effects in the FOURIER trial (N=27,564) were injection-site reactions, nasopharyngitis, and upper respiratory infections, not drowsiness or cognitive changes. The FOURIER investigators, writing in the New England Journal of Medicine, reported that evolocumab at 140 mg Q2W or 420 mg monthly reduced LDL cholesterol by 59% from a median baseline of 92 mg/dL and reduced the composite MACE endpoint by 15% (HR 0.85; 95% CI 0.79 to 0.92; P<0.001) over a median follow-up of 2.2 years.

Because evolocumab does not sedate, there is no clinically meaningful additive pharmacodynamic concern specific to this pairing.

Clinical Profile of Patients Who Take Both Drugs

The population taking evolocumab typically has established atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) with inadequate LDL reduction on maximally tolerated statins. The ACC/AHA 2022 Guideline on Cardiovascular Risk Reduction recommends PCSK9 inhibitor therapy when LDL-C remains above 70 mg/dL on maximally tolerated statin plus ezetimibe in very high-risk ASCVD patients.

Many of these patients are older adults managing several comorbidities, including depression and insomnia, which is exactly where trazodone tends to appear on the medication list. CDC data on antidepressant use in the United States show that among adults aged 60 and older, antidepressant use exceeds 19%, making co-prescription of a cardiac agent and a sedating antidepressant genuinely common.

Familial Hypercholesterolemia Patients

HoFH (homozygous familial hypercholesterolemia) and HeFH (heterozygous familial hypercholesterolemia) patients often begin PCSK9 inhibitor therapy at younger ages and continue for decades. A registry study published in the European Heart Journal found that anxiety and depression occur at elevated rates in FH patients, possibly linked to the chronic disease burden and fear of premature cardiovascular events. This further increases the likelihood of concurrent trazodone use in the FH population.

Post-MI and Post-Stroke Patients

Post-myocardial infarction and post-stroke patients are another large group prescribed evolocumab. Sleep disturbance and depressive symptoms are common after acute cardiovascular events, and trazodone is frequently chosen over benzodiazepines because it is non-habit-forming and does not suppress respiratory drive. The combination is therefore clinically logical, and the absence of a pharmacokinetic interaction supports it.

What the Major Drug Interaction Databases Say

Clinicians routinely consult commercial drug interaction databases when reviewing polypharmacy. Across the major platforms, the evolocumab-trazodone combination receives no interaction flag or receives a "no interaction found" designation. This reflects the mechanistic reality described above. The framework below summarizes how each interaction type applies:

| Interaction Type | Mechanism Involved | Applies to Evolocumab + Trazodone? | |---|---|---| | CYP3A4 kinetic | Enzyme inhibition/induction | No | | CYP2D6 kinetic | Enzyme inhibition/induction | No | | P-gp transporter | Efflux competition | No | | QTc prolongation (PD) | Additive ion channel effect | No (evolocumab has no QT signal) | | CNS sedation (PD) | Additive CNS depression | Minimal (evolocumab not sedating) | | Serotonin syndrome (PD) | 5-HT excess | No (evolocumab has no serotonergic activity) |

This table confirms that none of the standard interaction pathways applies to this pair.

QTc Considerations With Trazodone

Trazodone carries a low but real risk of QTc prolongation, particularly at high doses or in patients with electrolyte abnormalities. A pharmacovigilance analysis in the British Journal of Clinical Pharmacology found that trazodone-associated QTc prolongation is dose-dependent and amplified by hypokalemia, hypomagnesemia, and concurrent QT-prolonging medications.

Evolocumab has no cardiac ion channel activity. No QTc signal has appeared in evolocumab trials, including FOURIER (N=27,564) or PROFICIO (the broader clinical program). The combination does not increase QTc risk beyond what trazodone contributes alone. Baseline and periodic electrolyte monitoring in patients on trazodone remains good practice regardless of cardiovascular medications.

Monitoring Recommendations for Patients on Both Medications

Standard monitoring for each drug applies independently. No additional monitoring is required for the combination specifically.

Evolocumab Monitoring

• Fasting lipid panel 4 to 12 weeks after initiation or dose change, then every 3 to 12 months per ACC/AHA guidance.
• Injection-site assessment at each clinical contact.
• LDL-C target: below 70 mg/dL for very high-risk ASCVD; below 55 mg/dL in some European Society of Cardiology guidelines. ESC 2019 dyslipidemia guidelines define the 55 mg/dL threshold for extreme-risk patients.
• No hepatic or renal function monitoring required per FDA label.

Trazodone Monitoring

• Depression symptom scales (PHQ-9 or equivalent) at 4 to 8 weeks after initiation.
• Blood pressure (orthostatic hypotension risk, especially in older adults).
• Baseline ECG is reasonable in patients with pre-existing QTc prolongation or on other QT-prolonging drugs.
• Sodium levels in older adults (rare SIADH risk with all antidepressants).

What Does Not Need to Change

Providers do not need to alter evolocumab dosing, trazodone dosing, or injection scheduling based on the combination. Routine PCSK9 inhibitor follow-up visits provide natural checkpoints to review the entire medication list.

Patient Counseling Points

Patients who ask about this combination can be reassured directly. The following points are appropriate for a clinic visit or a telehealth consultation.

First, evolocumab works on LDL receptors in the liver and has no interaction with the brain chemistry affected by trazodone. The two drugs work in completely separate biological compartments using completely separate mechanisms.

Second, trazodone may cause morning drowsiness, especially at doses above 100 mg. This is a property of trazodone itself and should be discussed independent of evolocumab. Patients driving or operating machinery should be aware that trazodone sedation, not any interaction, is the relevant concern.

Third, the injection schedule for evolocumab (every two weeks or once monthly) does not need to be adjusted around trazodone dosing.

Fourth, any new symptom, including unexpected dizziness, palpitations, or worsening depression, should be reported promptly. These symptoms are not expected from this specific combination, but they should not be attributed to a phantom interaction when they occur. A thorough review of all medications and comorbidities is more useful.

Evolocumab Efficacy Context: Why Staying on Repatha Matters

Patients sometimes discontinue PCSK9 inhibitors over unfounded interaction concerns. The cardiovascular benefit of evolocumab in high-risk patients is substantial and well-documented.

In FOURIER, 27,564 patients with established ASCVD and LDL-C of at least 70 mg/dL on optimized statin therapy were randomized to evolocumab or placebo. Sabatine et al., writing in the New England Journal of Medicine in 2017, reported a 59% reduction in LDL-C (from median 92 mg/dL to 30 mg/dL), a 27% relative risk reduction in myocardial infarction, and a 21% relative risk reduction in stroke. The composite MACE endpoint fell by 15% (P<0.001).

A patient who stops evolocumab to avoid a non-existent interaction with trazodone loses this cardiovascular protection. Clinicians should proactively address interaction concerns before they lead to unnecessary discontinuation.

The GLAGOV trial (N=968), published in JAMA, found that evolocumab produced significant coronary plaque regression (percent atheroma volume reduced by 0.95% vs. A 0.05% increase with placebo; P<0.001), providing mechanistic evidence that the LDL reduction translates into structural arterial benefit. Nicholls et al., JAMA 2016.

Special Populations

Older Adults

Patients aged 65 and older are particularly likely to receive both evolocumab (for ASCVD secondary prevention) and trazodone (for sleep). In this group, trazodone's alpha-1 blockade can cause orthostatic hypotension. The American Geriatrics Society Beers Criteria lists trazodone as a drug with orthostatic hypotension risk in older adults. This is a trazodone-intrinsic concern, not an interaction with evolocumab. Prescribers should counsel older patients to rise slowly from bed at night, which is relevant in this group regardless of what cardiovascular medications are present.

Patients With Hepatic Impairment

Trazodone exposure increases in severe hepatic impairment because CYP3A4 activity is reduced. The trazodone FDA label recommends caution and lower doses in this setting. Evolocumab does not require dose adjustment in hepatic impairment per its FDA prescribing information, since proteolytic degradation is not affected by liver disease.

Patients With Renal Impairment

Neither drug requires renal dose adjustment. Evolocumab pharmacokinetics are not materially altered by renal function. Trazodone and its metabolites are primarily eliminated hepatically.

Trazodone Drug Interactions That Actually Matter

For completeness, the interactions clinicians should watch for with trazodone include the following categories. None involves evolocumab.

Strong CYP3A4 inhibitors, such as clarithromycin, itraconazole, ketoconazole, and ritonavir, can raise trazodone plasma concentrations by 2- to 6-fold, increasing sedation and QTc risk. Dose reduction of trazodone by 50% or more may be needed.

Strong CYP3A4 inducers, such as rifampin, phenytoin, carbamazepine, and St. John's wort, can reduce trazodone exposure substantially, reducing efficacy.

MAO inhibitors combined with trazodone carry a risk of serotonin syndrome. A washout of at least 14 days is required between an MAOI and trazodone.

Other serotonergic agents, including SSRIs, SNRIs, linezolid, and tramadol, may increase serotonin syndrome risk when combined with trazodone, though the absolute risk is low with careful dosing.

A 2014 review in CNS Drugs provided a comprehensive analysis of trazodone's CYP-mediated interactions and concluded that the CYP3A4 pathway represents the dominant clinical concern for this drug. Evolocumab is simply absent from all of these considerations.